Back to results
US 2025/0019428 A1Published application
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
AssigneeJanssen Biotech, Inc.
InventorsKristopher Barnthouse, Subinay Ganguly, Maarten Groeneveld, Manuel Lopez, JR., Michael Nedved, Kevin D. Smith
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody a recombinant anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.
Claims18
Anti-TNF antibodies comprising:
- a HC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6, wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
- a) total neutral oligosaccharide species >99.0%;
- b) total charged oligosaccharide species <1.0%;
- c) individual neutral oligosaccharide species G0F>60.0%;
- d) individual neutral oligosaccharide species G1F<20.0%;
- or
- e) individual neutral oligosaccharide species G2F<5.0%.
9 more elements
A method of manufacture for producing anti-TNF antibodies comprising:
- a HC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6, wherein the anti-TNF antibodies are produced by a method of manufacture comprising:
- a. culturing Chinese Hamster Ovary cells (CHO cells), wherein the CHO cells comprise a nucleic acid encoding the anti-TNF antibodies;
- b. expressing the anti-TNF antibodies in the CHO cells;
- and,
- c. purifying the anti-TNF antibodies,
- wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
- a) total neutral oligosaccharide species >99.0%;
- b) total charged oligosaccharide species <1.0%;
- c) individual neutral oligosaccharide species G0F>60.0%;
- d. individual neutral oligosaccharide species G1F<20.0%;
- or
- e. individual neutral oligosaccharide species G2F<5.0%.
14 more elements
A composition comprising anti-TNF antibodies:
- a HC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6, wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
- a) total neutral oligosaccharide species >99.0%;
- b) total charged oligosaccharide species <1.0%;
- c) individual neutral oligosaccharide species G0F>60.0%;
- d) individual neutral oligosaccharide species G1F<20.0%;
- or
- e) individual neutral oligosaccharide species G2F<5.0%.
9 more elements
Dependencies are inferred from the claim text.